Overcharging of price One-time settlement likely for pharma firms

  • News
  • September 15, 2016
New Delhi
The drug price controller has formulated the draft of a “one-time settlement plan” for pharma-ceutical companies that admit to over-charging. According to the proposal, the department of pharmaceuticals and the finance ministry will work together on the quantum of waiver on interest payment. As of June, the National Pharmaceutical Pricing Authority (NPPA) was to recover a total of Rs 4,567 crore, including interest, from pharma companies for overcharging.
The amount is subject to ongoing litigation, with cases being so contested in the courts being Rs 3,720 crore, it had said. The amount in question for overcharging cases still under process is Rs 772 crore. The initial idea came from the department of pharmaceuticals, which asked the NPPA to form a draft proposal, it is learnt. Final approval has to come from the finance ministry, which had earlier rejected a similar proposal.
NPPA has since its inception issued 1,389 demand notices to pharma companies. A sum of Rs 4,953 crore was demanded as overcharged amount, including interest, of which Rs 386.9 crore had been realised till end-June this year. NPPA’s mandate is to fix or revise the prices of controlled bulk drugs and formulations, and to enforce prices and availability of medicines. It has been entrusted with fixation of prices in the National List of Essential Medicines. And, monitors prices of drugs not subject to control, to check if these are at reasonable levels.

Related Posts

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

  • News
  • May 27, 2025
  • 268 views
Ramping Up Community for JeevanRaksha during Disasters

CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr